{
  "personality": null,
  "timestamp": "2025-10-11T04:34:51.837140",
  "category": "Health",
  "news_summary": "Advancements in gene editing, breakthroughs in understanding and treating chronic pain and fatigue, and inspiring personal recovery stories highlight promising progress in medical research and mental health.",
  "news_summary_fr": "Les avancées dans le domaine de l'édition de gènes, les percées dans la compréhension et le traitement de la douleur et de la fatigue chroniques, ainsi que les récits de guérison personnelle inspirants mettent en lumière les progrès prometteurs de la recherche médicale et de la santé mentale.",
  "news_summary_es": "Los avances en edición genética, los grandes progresos en la comprensión y el tratamiento del dolor crónico y la fatiga, y las inspiradoras historias de recuperación personal ponen de relieve los prometedores avances en investigación médica y salud mental.",
  "articles": [
    {
      "title": "MIT’s new precision gene editing tool could transform medicine",
      "summary": "MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we treat hundreds of genetic diseases. By fine-tuning the tiny molecular “tools” that rewrite DNA, they’ve created a new system that makes 60 times fewer mistakes than before.",
      "content": "A gene-editing approach called prime editing could one day help treat many illnesses by turning faulty genes into healthy ones. However, the technique sometimes introduces small mistakes into DNA, which can occasionally be harmful.\n\nResearchers at MIT have now discovered a way to significantly reduce these errors by altering the key proteins that drive the editing process. They believe this improvement could make gene therapy safer and more practical for treating a wide range of diseases.\n\n\"This paper outlines a new approach to doing gene editing that doesn't complicate the delivery system and doesn't add additional steps, but results in a much more precise edit with fewer unwanted mutations,\" says Phillip Sharp, an MIT Institute Professor Emeritus, a member of MIT's Koch Institute for Integrative Cancer Research, and one of the senior authors of the new study.\n\nUsing their refined method, the MIT team lowered the rate of mistakes in prime editing from roughly one in seven edits to about one in 101 for the most common editing type. In a more precise editing mode, the improvement went from one in 122 to one in 543.\n\n\"For any drug, what you want is something that is effective, but with as few side effects as possible,\" says Robert Langer, the David H. Koch Institute Professor at MIT, a member of the Koch Institute, and one of the senior authors of the new study. \"For any disease where you might do genome editing, I would think this would ultimately be a safer, better way of doing it.\"\n\nKoch Institute research scientist Vikash Chauhan led the study, which was recently published in Nature.\n\nThe potential for error\n\nIn the 1990s, early gene therapy efforts relied on inserting new genes into cells using modified viruses. Later, scientists developed techniques that used enzymes like zinc finger nucleases to directly repair genes. These enzymes worked but were difficult to reengineer for new DNA targets, making them slow and cumbersome to use.\n\nThe discovery of the CRISPR system in bacteria changed everything. CRISPR uses an enzyme called Cas9, guided by a piece of RNA, to cut DNA at a specific location. Researchers adapted it to remove faulty DNA sequences or insert corrected ones using an RNA-based template, making gene editing faster and more flexible.\n\nIn 2019, scientists at the Broad Institute of MIT and Harvard introduced prime editing, a new version of CRISPR that is even more precise and less likely to affect unintended areas of the genome. More recently, prime editing was used successfully to treat a patient with chronic granulomatous disease (CGD), a rare disorder that weakens white blood cells.\n\n\"In principle, this technology could eventually be used to address many hundreds of genetic diseases by correcting small mutations directly in cells and tissues,\" Chauhan says.\n\nOne of the advantages of prime editing is that it doesn't require making a double-stranded cut in the target DNA. Instead, it uses a modified version of Cas9 that cuts just one of the complementary strands, opening up a flap where a new sequence can be inserted. A guide RNA delivered along with the prime editor serves as the template for the new sequence.\n\nOne reason prime editing is considered safer is that it doesn’t cut both strands of DNA. Instead, it makes a gentler, single-strand cut using a modified Cas9 enzyme. This opens a small flap in the DNA where a new, corrected sequence can be inserted, guided by an RNA template.\n\nOnce the corrected sequence is added, it must replace the original DNA strand. If the old strand reattaches instead, the new fragment can sometimes end up in the wrong spot, leading to unintended errors.\n\nMost of these mistakes are harmless, but in rare cases they could contribute to tumor growth or other health issues. In current prime editing systems, the error rate can vary from about one in seven edits to one in 121, depending on the editing mode.\n\n\"The technologies we have now are really a lot better than earlier gene therapy tools, but there's always a chance for these unintended consequences,\" Chauhan says.\n\nPrecise editing\n\nTo reduce those error rates, the MIT team decided to take advantage of a phenomenon they had observed in a 2023 study. In that paper, they found that while Cas9 usually cuts in the same DNA location every time, some mutated versions of the protein show a relaxation of those constraints. Instead of always cutting the same location, those Cas9 proteins would sometimes make their cut one or two bases further along the DNA sequence.\n\nThis relaxation, the researchers discovered, makes the old DNA strands less stable, so they get degraded, making it easier for the new strands to be incorporated without introducing any errors.\n\nIn the new study, the researchers were able to identify Cas9 mutations that dropped the error rate to 1/20th its original value. Then, by combining pairs of those mutations, they created a Cas9 editor that lowered the error rate even further, to 1/36th the original amount.\n\nTo make the editors even more accurate, the researchers incorporated their new Cas9 proteins into a prime editing system that has an RNA binding protein that stabilizes the ends of the RNA template more efficiently. This final editor, which the researchers call vPE, had an error rate just 1/60th of the original, ranging from one in 101 edits to one in 543 edits for different editing modes. These tests were performed in mouse and human cells.\n\nThe MIT team is now working on further improving the efficiency of prime editors, through further modifications of Cas9 and the RNA template. They are also working on ways to deliver the editors to specific tissues of the body, which is a longstanding challenge in gene therapy.\n\nThey also hope that other labs will begin using the new prime editing approach in their research studies. Prime editors are commonly used to explore many different questions, including how tissues develop, how populations of cancer cells evolve, and how cells respond to drug treatment.\n\n\"Genome editors are used extensively in research labs,\" Chauhan says. \"So the therapeutic aspect is exciting, but we are really excited to see how people start to integrate our editors into their research workflows.\"\n\nThe research was funded by the Life Sciences Research Foundation, the National Institute of Biomedical Imaging and Bioengineering, the National Cancer Institute, and the Koch Institute Support (core) Grant from the National Cancer Institute.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251010091553.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-10",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a significant breakthrough in gene editing technology by MIT researchers that greatly reduces errors in prime editing, potentially transforming treatment for hundreds of genetic diseases. The improvement in precision and safety has broad implications for gene therapy and medical research, offering hope for safer, more effective treatments with wide-reaching health benefits. The article provides detailed context about the technology, its development, and potential impact, fulfilling criteria for inspiring good news.",
      "category": "Health",
      "personality_title": "MIT develops gene-editing tool that makes fewer mistakes",
      "personality_presentation": "**Context** – Gene editing is a way scientists change DNA to fix broken genes that cause diseases. A newer method called prime editing is more precise than older tools but still makes some mistakes that could be harmful.\n\n**What happened** – Researchers at MIT improved prime editing by changing the proteins that do the DNA cutting. Their new tool, called vPE, makes 60 times fewer errors than before. They tested it in mouse and human cells and found it much safer and more accurate.\n\n**Impact** – This is important because fewer mistakes mean gene therapies can be safer for patients. It could help treat many genetic diseases by fixing DNA more precisely without causing unwanted changes.\n\n**What's next step** – The MIT team will keep improving the tool and work on ways to deliver it to specific body parts. They also hope other scientists will use this new editing method to study diseases and develop treatments.\n\n**One-sentence takeaway** – MIT’s new gene-editing tool greatly reduces errors in DNA editing, making gene therapy safer and more effective for treating genetic diseases.",
      "personality_title_fr": "MIT développe un outil d’édition génétique beaucoup plus précis",
      "personality_presentation_fr": "**Contexte** – L’édition génétique permet aux scientifiques de modifier l’ADN pour réparer des gènes défectueux responsables de maladies. Une méthode récente appelée édition prime est plus précise que les anciennes, mais elle peut encore provoquer des erreurs parfois dangereuses.\n\n**Ce qui s’est passé** – Des chercheurs du MIT ont amélioré l’édition prime en modifiant les protéines qui coupent l’ADN. Leur nouvel outil, nommé vPE, fait 60 fois moins d’erreurs qu’avant. Ils l’ont testé sur des cellules de souris et humaines, et il est beaucoup plus sûr et précis.\n\n**Impact** – C’est important car moins d’erreurs signifie que les thérapies géniques seront plus sûres pour les patients. Cela pourrait aider à traiter de nombreuses maladies génétiques en corrigeant l’ADN de façon plus précise, sans changer d’autres parties.\n\n**Étape suivante** – L’équipe du MIT va continuer à améliorer cet outil et chercher comment le livrer dans des parties précises du corps. Ils espèrent aussi que d’autres scientifiques utiliseront cette nouvelle méthode pour étudier les maladies et développer des traitements.\n\n**Résumé en une phrase** – Le nouvel outil d’édition génétique du MIT réduit fortement les erreurs, rendant les thérapies géniques plus sûres et efficaces pour traiter les maladies génétiques.",
      "personality_title_es": "MIT crea una herramienta de edición genética con menos errores",
      "personality_presentation_es": "**Contexto** – La edición genética es una forma en que los científicos cambian el ADN para arreglar genes dañados que causan enfermedades. Un método nuevo llamado edición prime es más preciso que los anteriores, pero aún puede provocar errores que a veces son dañinos.\n\n**Qué pasó** – Investigadores del MIT mejoraron la edición prime modificando las proteínas que cortan el ADN. Su nueva herramienta, llamada vPE, comete 60 veces menos errores que antes. La probaron en células de ratones y humanas y resultó más segura y precisa.\n\n**Impacto** – Esto es importante porque menos errores significan que las terapias génicas pueden ser más seguras para los pacientes. Podría ayudar a tratar muchas enfermedades genéticas corrigiendo el ADN con mayor precisión sin causar cambios no deseados.\n\n**Próximo paso** – El equipo del MIT seguirá mejorando la herramienta y trabajando en cómo llevarla a partes específicas del cuerpo. También esperan que otros científicos usen este nuevo método para estudiar enfermedades y crear tratamientos.\n\n**Resumen en una frase** – La nueva herramienta de edición genética del MIT reduce mucho los errores, haciendo que la terapia génica sea más segura y efectiva para tratar enfermedades genéticas.",
      "image_url": "public/images/news_image_MITs-new-precision-gene-editing-tool-could-transfo.png",
      "image_prompt": "A detailed, warm-toned painting of intertwined DNA strands gently being repaired by glowing, stylized molecular tools resembling soft, precise mechanical hands, with subtle light beams symbolizing improved accuracy and care, set against a simple, natural background of softly blended pastel colors."
    },
    {
      "title": "Scientists discover brain circuit that can switch off chronic pain",
      "summary": "Scientists have pinpointed Y1 receptor neurons in the brain that can override chronic pain signals when survival instincts like hunger or fear take precedence. Acting like a neural switchboard, these cells balance pain with other biological needs. The research could pave the way for personalized treatments that target pain at its brain source—offering hope for millions living with long-term pain.",
      "content": "Pain may be unpleasant, but in most cases it plays a vital, even lifesaving, role. Short bursts of pain act as warning signals that protect us from harm. When you touch a hot pan, stub your toe, or bump your head, your nervous system instantly delivers an “Ow!” that prompts you to pull back before more damage occurs. The pain fades, the body heals, and you remember what not to do next time.\n\n\n\nChronic pain, however, is an entirely different story. In this condition, the warning signal doesn’t stop even after the injury has healed. For about 50 million people in the United States, pain becomes a constant, invisible companion that can persist for years or even decades. \"It's not just an injury that won't heal,\" explains neuroscientist at the University of Pennsylvania J. Nicholas Betley, \"it's a brain input that's become sensitized and hyperactive, and determining how to quiet that input could lead to better treatments.\"\n\nBetley, along with collaborators from the University of Pittsburgh and Scripps Research Institute, has discovered an important piece of the chronic pain puzzle. Their research points to a specific group of brainstem cells called Y1 receptor (Y1R)-expressing neurons, located in the lateral parabrachial nucleus (lPBN). These neurons are activated in persistent pain states, but they also process signals related to hunger, fear, and thirst. This suggests that the brain can adjust pain responses when other, more urgent needs demand attention.\n\nThe findings, published in Nature, indicate that relief may be possible because, as the researchers write, \"there are circuits in the brain that can reduce the activity of neurons that transmit the signal of pain.\"\n\nTracking pain in the brain\n\nWorking with the Taylor lab at the University of Pittsburgh, Betley’s team used calcium imaging to visualize neuron activity in real time in animal models of both short-term and long-term pain. They observed that Y1R neurons did not simply react to quick bursts of pain; instead, they kept firing steadily during prolonged pain, a phenomenon known as “tonic activity.”\n\nBetley compares this to an engine left running even after you’ve parked the car. The pain signals continue to hum in the background even when physical recovery seems complete. This ongoing neural activity may explain why some people continue to feel pain long after an injury or surgery.\n\nThe research originated from an unexpected observation Betley made after joining Penn in 2015: hunger seemed to lessen chronic pain.\n\n\"From my own experience, I felt that when you're really hungry you'll do almost anything to get food,\" he says. \"When it came to chronic, lingering pain, hunger seemed to be more powerful than Advil at reducing pain.\"\n\nThat insight inspired further investigation. Former graduate student Nitsan Goldstein found that other critical survival states—such as thirst and fear—can also suppress long-term pain. In collaboration with the Kennedy lab at Scripps, the team showed that the brain’s parabrachial nucleus can filter sensory input to quiet pain when immediate survival takes priority.\n\n\"That told us the brain must have a built-in way of prioritizing urgent survival needs over pain, and we wanted to find the neurons responsible for that switch,\" says Goldstein.\n\nA key part of that switch is neuropeptide Y (NPY), a signaling molecule that helps the brain juggle competing needs. When hunger or fear takes priority, NPY acts on Y1 receptors in the parabrachial nucleus to dampen ongoing pain signals.\n\n\"It's like the brain has this built-in override switch,\" Goldstein explains. \"If you're starving or facing a predator, you can't afford to be overwhelmed by lingering pain. Neurons activated by these other threats release NPY, and NPY quiets the pain signal so that other survival needs take precedence.\"\n\nA scattered signal\n\nThe researchers also characterized the molecular and anatomical identity of the Y1R neurons in the lPBN. They found that Y1Rneurons didn't form two tidy anatomical or molecular populations. Instead, these neurons were scattered across many other cell types.\n\n\"It's like looking at cars in a parking lot,\" Betley says. \"We expected all the Y1R neurons to be a cluster of yellow cars parked together, but here the Y1R neurons are like yellow paint distributed across red cars, blue cars, and green cars. We don't know exactly why, but we think this mosaic distribution may allow the brain to dampen different kinds of painful inputs across multiple circuits.\"\n\nExplorations of pain treatment\n\nWhat excites Betley with this discovery is the further exploration of its potential to \"use Y1 neural activity as a biomarker for chronic pain, something drug developers and clinicians have long lacked,\" he says.\n\n\"Right now, patients may go to an orthopedist or a neurologist, and there is no clear injury. But they're still in pain,\" he says. \"What we're showing is that the problem may not be in the nerves at the site of injury, but in the brain circuit itself. If we can target these neurons, that opens up a whole new path for treatment.\"\n\nThis research also suggests that behavioral interventions such as exercise, meditation, and cognitive behavioral therapy may influence how these brain circuits fire, just as hunger and fear did in the lab.\n\n\"We've shown that this circuit is flexible, it can be dialed up or down,\" he says. \"So, the future isn't just about designing a pill. It's also about asking how behavior, training, and lifestyle can change the way these neurons encode pain.\"\n\nJ Nicholas Betley is an associate professor in the Department of Biology at the University of Pennsylvania's School of Arts & Sciences.\n\nNitsan Goldstein was a graduate student in the Betley Lab at Penn Arts & Sciences during this study. He is currently a postdoctoral researcher at the Massachusetts Institute of Technology.\n\nOther authors include Michelle Awh, Lavinia Boccia, Jamie R. E. Carty, Ella Cho, Morgan Kindel, Kayla A. Kruger, Emily Lo, Erin L. Marble, Nicholas K. Smith, Rachael E. Villari, and Albert T. M. Yeung of Penn Arts & Sciences; Niklas Blank and Christoph A. Thaiss of Penn's Perelman School of Medicine; Melissa J. Chee and Yasmina Dumiaty of Carleton University; Rajesh Khanna of University of Florida College of Medicine,; Ann Kennedy and Amadeus Maes of Scripps Research Institute; and Heather N. Allen, Tyler S. Nelson and Bradley K. Taylor of the University of Pittsburg.\n\nThis research was supported by the Klingenstein Foundation, the University of Pennsylvania School of Arts and Sciences, the National Institutes of Health (grants F31DK131870, 1P01DK119130, 1R01DK133399, 1R01DK124801, 1R01NS134976, F32NS128392, K00NS124190, F32DK135401, T32DK731442, R61NS126026, R01NS120663, R01NS134976-02, R00MH117264, 1DP1DK140021-01), the National Science Foundation Graduate Research Fellowship Program, the Blavatnik Family Foundation Fellowship, the American Neuromuscular Foundation Development Grant, the American Heart Association (25POST1362884), the Swiss National Science Foundation (206668), the Canadian Institutes of Health Research Project Grant (PJT-175156), the Simons Foundation, a McKnight Foundation Scholar Award, and a Pew Biomedical Scholar Award.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251009033126.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-10",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant scientific discovery identifying a brain circuit that can switch off chronic pain, which affects millions globally. This breakthrough offers hope for new, personalized treatments targeting the brain's pain pathways, potentially improving quality of life for many suffering from chronic pain. The research is detailed, focused on a single major advancement, and has broad implications for health and medicine.",
      "category": "Health",
      "personality_title": "Scientists find brain circuit that can turn off chronic pain",
      "personality_presentation": "**Context** – Pain helps protect us by warning about danger, like touching something hot. But chronic pain lasts long after an injury heals, affecting about 50 million people in the U.S. This type of pain comes from ongoing signals in the brain, not just the injury itself.\n\n**What happened** – Researchers from the University of Pennsylvania and other institutions discovered special brain cells called Y1 receptor neurons in an area called the lateral parabrachial nucleus. These cells act like a switch that can reduce chronic pain signals, especially when the brain focuses on urgent needs like hunger or fear. They used imaging techniques to watch these neurons in animals and found they stay active during long-term pain.\n\n**Impact** – This discovery shows that the brain has a natural way to lower chronic pain when other survival needs are more important. It helps explain why pain can sometimes fade when people are very hungry or scared. Understanding these brain circuits could lead to new treatments that target the brain directly, rather than just treating the injured body part.\n\n**What's next step** – Scientists want to use this knowledge to develop better pain medicines and find ways to measure chronic pain through brain activity. They also hope to explore how behaviors like exercise or meditation might change these brain signals to reduce pain without drugs.\n\n**One-sentence takeaway** – Scientists have identified brain cells that can switch off chronic pain signals, opening new paths for better treatments focused on the brain.\n",
      "personality_title_fr": "Des scientifiques découvrent un circuit cérébral qui peut arrêter la douleur chronique",
      "personality_presentation_fr": "**Contexte** – La douleur nous protège en avertissant d’un danger, comme toucher quelque chose de chaud. Mais la douleur chronique dure longtemps après la guérison d’une blessure et touche environ 50 millions de personnes aux États-Unis. Cette douleur vient de signaux persistants dans le cerveau, pas seulement de la blessure elle-même.\n\n**Ce qui s’est passé** – Des chercheurs de l’Université de Pennsylvanie et d’autres institutions ont découvert des cellules cérébrales spéciales appelées neurones des récepteurs Y1 dans une zone appelée le noyau parabrachial latéral. Ces cellules agissent comme un interrupteur qui peut réduire les signaux de douleur chronique, surtout quand le cerveau se concentre sur des besoins urgents comme la faim ou la peur. Ils ont utilisé des techniques d’imagerie pour observer ces neurones chez des animaux et ont constaté qu’ils restent actifs lors de douleurs à long terme.\n\n**Impact** – Cette découverte montre que le cerveau possède un moyen naturel de diminuer la douleur chronique quand d’autres besoins de survie sont plus importants. Elle aide à comprendre pourquoi la douleur peut parfois s’estomper quand une personne a très faim ou est effrayée. Comprendre ces circuits cérébraux pourrait mener à de nouveaux traitements ciblant directement le cerveau, plutôt que seulement la partie blessée du corps.\n\n**Prochaine étape** – Les scientifiques veulent utiliser cette connaissance pour développer de meilleurs médicaments contre la douleur et trouver des façons de mesurer la douleur chronique grâce à l’activité cérébrale. Ils espèrent aussi explorer comment des comportements comme l’exercice ou la méditation pourraient modifier ces signaux cérébraux pour réduire la douleur sans médicaments.\n\n**Une phrase clé** – Des scientifiques ont identifié des cellules cérébrales capables d’éteindre les signaux de douleur chronique, ouvrant de nouvelles voies pour de meilleurs traitements ciblant le cerveau.\n",
      "personality_title_es": "Científicos descubren circuito cerebral que puede apagar el dolor crónico",
      "personality_presentation_es": "**Contexto** – El dolor nos protege advirtiendo sobre peligros, como tocar algo caliente. Pero el dolor crónico dura mucho tiempo después de que una herida sana y afecta a unos 50 millones de personas en Estados Unidos. Este dolor viene de señales continuas en el cerebro, no solo de la lesión.\n\n**Qué pasó** – Investigadores de la Universidad de Pensilvania y otras instituciones encontraron células cerebrales especiales llamadas neuronas con receptores Y1 en una zona llamada núcleo parabranquial lateral. Estas células funcionan como un interruptor que puede reducir las señales de dolor crónico, especialmente cuando el cerebro se enfoca en necesidades urgentes como el hambre o el miedo. Usaron técnicas de imagen para observar estas neuronas en animales y vieron que permanecen activas durante el dolor prolongado.\n\n**Impacto** – Este hallazgo muestra que el cerebro tiene una forma natural de bajar el dolor crónico cuando otras necesidades de supervivencia son más importantes. Ayuda a explicar por qué el dolor puede desaparecer cuando una persona tiene mucha hambre o miedo. Entender estos circuitos cerebrales podría llevar a nuevos tratamientos que enfoquen el cerebro directamente, en lugar de solo tratar la parte lesionada.\n\n**Próximo paso** – Los científicos quieren usar este conocimiento para crear mejores medicinas para el dolor y encontrar formas de medir el dolor crónico a través de la actividad cerebral. También esperan explorar cómo actividades como el ejercicio o la meditación podrían cambiar estas señales cerebrales para reducir el dolor sin medicamentos.\n\n**Una frase clave** – Científicos han identificado células cerebrales que pueden apagar las señales del dolor crónico, abriendo nuevas oportunidades para mejores tratamientos centrados en el cerebro.\n",
      "image_url": "public/images/news_image_Scientists-discover-brain-circuit-that-can-switch-.png",
      "image_prompt": "A warm, detailed painting of a softly glowing neural network shaped like a brainstem, where scattered golden sparks (representing Y1 receptor neurons) gently dim and quiet vibrant red pulses symbolizing chronic pain signals, intertwined with subtle flowing ribbons of blue and green light symbolizing hunger, fear, and thirst overriding the pain, all rendered in natural, muted earth tones and soft pastels on a simple, abstract background."
    },
    {
      "title": "'How growing a sunflower helped me fight anorexia'",
      "summary": "'Green social prescribing' schemes are being used by NHS doctors to improve patients' mental health.",
      "content": "'How growing a sunflower helped me fight anorexia'\n\n23 hours ago Share Save Malcolm Prior and Jenny Kumah BBC News rural affairs team Share Save\n\nAndy Alcroft/BBC Emily Hough is now using her experiences to help shape nature prescribing schemes\n\nFor Emily Hough, nature was too often simply something \"out there\", a world apart from her, a view from a hospital window. Years spent in and out of specialist mental health units in Birmingham and London, being treated for the eating disorder she had had since the age of 12, meant she felt little connection with the countryside or interest in the everyday flora and fauna around her. That was until five years ago, when a hospital occupational therapist gave her an unusual prescription: Grow a sunflower. \"I'll be honest I'd never planted anything in my life,\" Ms Hough said.\n\n\"But I planted that sunflower and, just watching it grow, from me watering it and from me protecting it from the shade, helped me feel connected for the first time and really be able to appreciate what was around me - and how I can make a difference to nature and what nature can actually do for me. \"I was in a hospital at that point, so it was very limited. Fast forward five years, here we are today.\"\n\nGetty Images Green social prescribing encourages people to take part in nature-based activities to benefit their health and wellbeing\n\nFrom those early roots, Ms Hough, now 35, embraced what is formally called by the NHS \"green social prescribing\", where GPs and health practitioners refer patients to organisations that offer nature-based activities, whether that be hiking, birdwatching, rockpooling or looking after a city-based allotment. It is supposed to complement other more mainstream treatments and therapies and has been a key part of the government's 10-year plan for the NHS in England. The scheme may not work for everyone but for Ms Hough, who has now relocated from Solihull to a life in the countryside, the benefits have been profound. She is now out of hospital and has become what the NHS calls an \"Expert by Experience\" (EbE) - someone who uses that experience to design and evaluate new health services. She helped shape the Royal Society for the Protection of Birds (RSPB)'s flagship \"nature prescription\" scheme for the West Midlands, launched earlier this year. On Friday – World Mental Health Day - the scheme marks the training of its 100th health professional, with enough resources to support 1,000 patients accessing nature-based activities.\n\nAndy Alcroft/BBC Dom Higgins, from the Wildlife Trusts, saids the evidence in favour of green social prescribing was clear\n\nBut the future of green social prescribing is uncertain. Despite a four-year national pilot that ended in March being judged a success by an independent evaluation of its first two years, there is concern that the onus for funding these schemes is being left to charities. Organisations, including The Wildlife Trusts, the RSPB and the Ocean Conservation Trust, are calling on the government to commit more funding to nature prescription schemes and to roll them out, beyond their initial seven trial areas. Dom Higgins, head of health and education for The Wildlife Trusts, said: \"It is unequivocal that nature improves mental health. \"I think the time for questioning the evidence is really over and people within the system and the NHS and decision makers get this. \"It's just we need the mechanism to make it available everywhere. It's time to seriously fund prevention and opportunities for people to create good health in the neighbourhoods where they live and work.\" The national pilot scheme saw nearly 8,500 people prescribed nature activities in its first two years, with more than half those patients living in socio-economically deprived areas. Chris Dayson, professor of voluntary action, health and wellbeing at Sheffield Hallam University, who was part of the team that evaluated the scheme, said it brought \"a really statistically significant increase in wellbeing\" for patients. The evaluation also found the scheme brought an economic social return - not least of all by getting people back into work - of £2.42 for every £1 invested. When approached by the BBC, the government did not comment on the future of green social prescribing but said the evaluation of the second two years of the trial scheme would be published \"in due course\".\n\n'Dramatic results'",
      "url": "https://www.bbc.com/news/articles/c33rgvr0p5no?at_medium=RSS&at_campaign=rss",
      "source": "BBC News",
      "published": "2025-10-10",
      "sentiment_score": 0.85,
      "reasoning": "The article reports on the positive impact of NHS 'green social prescribing' schemes that use nature-based activities to improve mental health, showing significant wellbeing improvements and economic benefits. It highlights a meaningful, scalable health intervention with broad public relevance and detailed context.",
      "category": "Health",
      "personality_title": "How nature prescriptions are helping mental health patients recover",
      "personality_presentation": "**Context** – Many people with mental health problems find it hard to connect with the world around them. The NHS in England has started using \"green social prescribing,\" where doctors suggest nature activities to help patients feel better alongside regular treatments.\n\n**What happened** – Emily Hough, who struggled with anorexia since she was 12, was given a unique prescription by a hospital worker: to grow a sunflower. Watching the sunflower grow helped her feel connected to nature for the first time. Over five years, she became involved in shaping nature-based health programs and now helps design these schemes. The NHS has trained 100 health professionals to support 1,000 patients in nature activities like hiking and gardening.\n\n**Impact** – This approach has shown clear benefits. A national pilot gave nearly 8,500 people prescriptions for nature activities, especially helping those in poorer areas. Patients reported better wellbeing, and the program helped some return to work. For every £1 spent, the scheme generated £2.42 in social and economic benefits. Experts say the evidence is strong that nature improves mental health.\n\n**What's next step** – While the pilot was successful, its future funding is uncertain. Charities currently support much of the work, and groups like The Wildlife Trusts and the RSPB want the government to invest more and expand the program beyond the original trial areas. A full report on the pilot’s later stages will be released soon.\n\n**One-sentence takeaway** – NHS nature prescriptions are improving mental health and wellbeing, offering a cost-effective way to support recovery through simple activities like growing plants or spending time outdoors.",
      "personality_title_fr": "Comment les prescriptions nature aident les patients à retrouver la santé mentale",
      "personality_presentation_fr": "**Contexte** – Beaucoup de personnes souffrant de problèmes de santé mentale ont du mal à se sentir connectées au monde qui les entoure. Le NHS en Angleterre utilise désormais la « prescription sociale verte », où les médecins recommandent des activités en pleine nature pour aider les patients à aller mieux en complément des traitements habituels.\n\n**Ce qui s'est passé** – Emily Hough, qui a souffert d'anorexie depuis l'âge de 12 ans, a reçu une prescription particulière d'un professionnel hospitalier : faire pousser un tournesol. Voir ce tournesol grandir l'a aidée à se sentir connectée à la nature pour la première fois. En cinq ans, elle a participé à la création de programmes de santé basés sur la nature et aide maintenant à concevoir ces initiatives. Le NHS a formé 100 professionnels de santé pour soutenir 1 000 patients dans des activités comme la randonnée et le jardinage.\n\n**Impact** – Cette méthode montre des bienfaits clairs. Un projet pilote national a prescrit des activités nature à près de 8 500 personnes, en aidant particulièrement celles vivant dans des zones défavorisées. Les patients ont ressenti une amélioration de leur bien-être, et certains ont pu reprendre le travail. Pour chaque livre dépensée, le programme a généré 2,42 livres en bénéfices sociaux et économiques. Les experts affirment que la preuve est solide que la nature améliore la santé mentale.\n\n**Prochaine étape** – Bien que le projet pilote ait été réussi, son financement futur est incertain. Les associations soutiennent actuellement une grande partie du travail, et des groupes comme The Wildlife Trusts et le RSPB demandent au gouvernement d'investir davantage et d'étendre le programme au-delà des zones d'essai initiales. Un rapport complet sur les dernières phases du projet sera bientôt publié.\n\n**En résumé** – Les prescriptions nature du NHS améliorent la santé mentale et le bien-être, offrant un moyen rentable de soutenir la guérison grâce à des activités simples comme cultiver des plantes ou passer du temps dehors.",
      "personality_title_es": "Cómo las recetas de naturaleza ayudan a pacientes a recuperar su salud mental",
      "personality_presentation_es": "**Contexto** – Muchas personas con problemas de salud mental tienen dificultad para sentirse conectadas con el mundo que las rodea. El NHS en Inglaterra ha comenzado a usar la «prescripción social verde», donde los médicos recomiendan actividades en la naturaleza para ayudar a los pacientes a mejorar junto con los tratamientos habituales.\n\n**Qué pasó** – Emily Hough, que luchó contra la anorexia desde los 12 años, recibió una receta especial de un trabajador hospitalario: cultivar un girasol. Ver crecer el girasol la ayudó a sentirse conectada con la naturaleza por primera vez. En cinco años, participó en diseñar programas de salud basados en la naturaleza y ahora ayuda a crear estas iniciativas. El NHS ha entrenado a 100 profesionales de salud para apoyar a 1,000 pacientes en actividades como senderismo y jardinería.\n\n**Impacto** – Este método ha mostrado beneficios claros. Un piloto nacional dio recetas para actividades en la naturaleza a casi 8,500 personas, ayudando especialmente a quienes viven en zonas pobres. Los pacientes reportaron mejor bienestar y algunos volvieron a trabajar. Por cada £1 invertida, el programa generó £2.42 en beneficios sociales y económicos. Los expertos dicen que la evidencia es fuerte de que la naturaleza mejora la salud mental.\n\n**Próximo paso** – Aunque el piloto fue exitoso, su financiamiento futuro es incierto. Actualmente, las organizaciones benéficas apoyan gran parte del trabajo, y grupos como The Wildlife Trusts y el RSPB piden al gobierno invertir más y expandir el programa fuera de las áreas de prueba originales. Un informe completo sobre las etapas finales del piloto será publicado pronto.\n\n**Conclusión en una frase** – Las recetas de naturaleza del NHS están mejorando la salud mental y el bienestar, ofreciendo una manera rentable de apoyar la recuperación mediante actividades simples como cultivar plantas o pasar tiempo al aire libre.",
      "image_url": "public/images/news_image_How-growing-a-sunflower-helped-me-fight-anorexia.png",
      "image_prompt": "A detailed, warm painting of a single tall sunflower growing vibrantly inside a softly lit hospital window frame, its golden petals reaching toward the light, surrounded by gentle hands watering and shielding it, symbolizing healing and connection through nature, rendered in natural, muted earth tones and soft greens."
    },
    {
      "title": "First proposed blood test for chronic fatigue syndrome: what scientists think",
      "summary": "Nature, Published online: 09 October 2025; doi:10.1038/d41586-025-03299-8A blood test has achieved 96% accuracy in diagnosing the condition in a small study of individuals. What does the test detect, and is it a biomarker of the condition?",
      "content": "Scientists have developed a blood test that analyses epigenetic changes in immune cells. They say it could be used to diagnose chronic fatigue syndrome. Credit: TEK Image/Science Photo Library\n\nResearchers who are seeking ways to diagnose a mysterious illness called chronic fatigue syndrome might have a new weapon in their armoury. In a study published in the Journal of Translational Medicine on 8 October1, scientists in the United Kingdom say they have found a way to distinguish epigenetic changes in the cells of people who have the condition, which is also known as myalgic encephalomyelitis.\n\nA debilitating long-term illness, ME/CFS affects between 17 million and 24 million people worldwide2, but these numbers are crude estimates because clinicians have long lacked reliable diagnostic tools for this poorly understood condition.\n\nThe results of the study show that the epigenetic test could be developed into a clinical biomarker for ME/CFS, said Dmitry Pshezhetskiy, a researcher–clinician at the University of East Anglia in Norwich, UK, and lead author of the study, in a press release that was published alongside the paper. “With no definitive tests, many patients have gone undiagnosed or misdiagnosed for years.” He added that the discovery “offers the potential for a simple, accurate blood test to help confirm a diagnosis, which could lead to earlier support and more effective management”.\n\nOthers in the field have cautiously welcomed the findings, but they point out that the study was small and that more work is needed to convert the technique into a clinical tool.\n\nA reboot for chronic fatigue syndrome research\n\nEpigenetic markers\n\nThe underlying mechanisms of ME/CFS remain unclear, but evidence is building that one of the hallmarks of ME/CFS is immune dysregulation. The authors had already developed an assay that screens for epigenetic changes in immune cells in the blood, which they used to identify epigenetic signatures for a range of conditions including rheumatoid arthritis3. The assay analyses the way DNA is folded inside peripheral blood mononuclear cells, a key part of the immune system.\n\nThe researchers tested whether the same assay could be used to screen for similar epigenetic changes to immune cells in the blood of 47 individuals with severe ME/CFS, comparing the results with those from 61 healthy participants. The data showed that the assay achieved a 96% accuracy in diagnosing people with ME/CFS.\n\nThe authors found a network of genomic changes that were strongly involved in immune and inflammatory signalling. The authors say that this is consistent with an immune-dysregulation signal in ME/CFS, and underscores the strength of using these changes as biomarkers of the condition. And they say the changes they identified can be connected to specific regions of non-coding DNA, which can help to unpick the role of genetics in the condition and lead to a better mechanistic understanding.\n\n“I think it’s really cool they brought this method to the field,” says Katie Glass, a molecular biologist who studies ME/CFS at Cornell University in Ithaca, New York. “As far as it being a biomarker, my enthusiasm would be pretty tempered because the cohort is very small and they looked at only very severe patients.”\n\nBiological underpinnings of chronic fatigue syndrome begin to emerge\n\nMany studies using various techniques to analyse everything from metabolites to free-floating RNA in the blood have identified several apparent signatures of ME/CFS, adds Glass, who previously had the condition but has now recovered.",
      "url": "https://www.nature.com/articles/d41586-025-03299-8",
      "source": "Nature",
      "published": "2025-10-11",
      "sentiment_score": 0.85,
      "reasoning": "The article reports on a significant scientific breakthrough: a blood test with 96% accuracy for diagnosing chronic fatigue syndrome (ME/CFS), a debilitating illness affecting millions worldwide. This development addresses a major unmet medical need by potentially enabling earlier and more accurate diagnosis, which could lead to better patient management and support. The study, while preliminary and small, provides substantial context on the test's scientific basis and its implications, making it a meaningful advancement in health research with broad societal impact.",
      "category": "Health",
      "personality_title": "New blood test shows promise for diagnosing chronic fatigue syndrome",
      "personality_presentation": "**Context** – Chronic fatigue syndrome, also called myalgic encephalomyelitis (ME/CFS), is a long-lasting illness that causes extreme tiredness and other symptoms. It affects millions of people worldwide, but doctors have struggled to diagnose it accurately because there is no clear test.\n\n**What happened** – Scientists in the United Kingdom developed a blood test that looks for special changes called epigenetic markers in immune cells. These markers show how the DNA is folded in the cells. In a small study with 47 patients who had severe ME/CFS and 61 healthy people, the test correctly identified those with the illness 96% of the time.\n\n**Impact** – This test could become the first reliable way to diagnose ME/CFS using a simple blood sample. Right now, many patients wait years or get the wrong diagnosis. Finding these unique DNA changes helps scientists understand how the illness affects the immune system and might lead to better treatments.\n\n**What's next step** – Researchers need to test the blood test on more people, including those with milder symptoms, to make sure it works well for everyone. If successful, this test could become a tool doctors use in clinics to confirm ME/CFS earlier and help patients get support sooner.\n\n**One-sentence takeaway** – A new blood test detecting DNA changes in immune cells shows high accuracy in diagnosing chronic fatigue syndrome, offering hope for better diagnosis and understanding of the illness.",
      "personality_title_fr": "Un nouveau test sanguin prometteur pour diagnostiquer le syndrome de fatigue chronique",
      "personality_presentation_fr": "**Contexte** – Le syndrome de fatigue chronique, aussi appelé encéphalomyélite myalgique (EM/SFC), est une maladie de longue durée provoquant une grande fatigue et d’autres symptômes. Elle touche des millions de personnes dans le monde, mais les médecins ont du mal à la diagnostiquer précisément car aucun test clair n’existe.\n\n**Ce qui s’est passé** – Des scientifiques du Royaume-Uni ont mis au point un test sanguin qui détecte des modifications spéciales appelées marqueurs épigénétiques dans les cellules immunitaires. Ces marqueurs montrent comment l’ADN est replié dans ces cellules. Dans une petite étude avec 47 patients atteints d’EM/SFC sévère et 61 personnes en bonne santé, le test a correctement identifié la maladie dans 96 % des cas.\n\n**Impact** – Ce test pourrait devenir la première méthode fiable pour diagnostiquer l’EM/SFC grâce à une simple prise de sang. Actuellement, beaucoup de patients attendent des années ou sont mal diagnostiqués. Identifier ces changements uniques dans l’ADN aide les scientifiques à mieux comprendre comment la maladie affecte le système immunitaire et pourrait conduire à de meilleurs traitements.\n\n**Prochaine étape** – Les chercheurs doivent tester ce test sanguin sur un plus grand nombre de personnes, y compris celles avec des symptômes plus légers, pour vérifier son efficacité pour tous. S’il fonctionne bien, ce test pourrait être utilisé par les médecins en clinique pour confirmer plus tôt l’EM/SFC et aider les patients plus rapidement.\n\n**Résumé en une phrase** – Un nouveau test sanguin détectant des modifications de l’ADN dans les cellules immunitaires montre une grande précision pour diagnostiquer le syndrome de fatigue chronique, ouvrant la voie à un meilleur diagnostic et à une meilleure compréhension de la maladie.",
      "personality_title_es": "Nuevo análisis de sangre prometedor para diagnosticar el síndrome de fatiga crónica",
      "personality_presentation_es": "**Contexto** – El síndrome de fatiga crónica, también llamado encefalomielitis miálgica (EM/SFC), es una enfermedad de larga duración que causa cansancio extremo y otros síntomas. Afecta a millones de personas en todo el mundo, pero los médicos tienen dificultades para diagnosticarla con precisión porque no existe una prueba clara.\n\n**Qué pasó** – Científicos del Reino Unido desarrollaron un análisis de sangre que detecta cambios especiales llamados marcadores epigenéticos en las células inmunitarias. Estos marcadores muestran cómo se pliega el ADN dentro de las células. En un pequeño estudio con 47 pacientes con EM/SFC grave y 61 personas sanas, la prueba identificó correctamente a los enfermos en el 96 % de los casos.\n\n**Impacto** – Esta prueba podría convertirse en la primera forma confiable de diagnosticar la EM/SFC usando una simple muestra de sangre. Actualmente, muchos pacientes esperan años o reciben un diagnóstico incorrecto. Encontrar estos cambios únicos en el ADN ayuda a los científicos a entender mejor cómo la enfermedad afecta al sistema inmunitario y podría llevar a mejores tratamientos.\n\n**Próximo paso** – Los investigadores deben probar la prueba en más personas, incluyendo quienes tienen síntomas más leves, para asegurarse de que funcione bien para todos. Si tiene éxito, esta prueba podría usarse en clínicas para confirmar la EM/SFC antes y ayudar a los pacientes más rápido.\n\n**Resumen en una frase** – Un nuevo análisis de sangre que detecta cambios en el ADN de las células inmunitarias muestra alta precisión para diagnosticar el síndrome de fatiga crónica, ofreciendo esperanza para un mejor diagnóstico y comprensión de la enfermedad.",
      "image_url": "public/images/news_image_First-proposed-blood-test-for-chronic-fatigue-synd.png",
      "image_prompt": "An intricate, warm-toned painting of a glowing blood sample vial surrounded by softly illuminated, stylized immune cells with delicate DNA strands gently unfolding and intertwining around them, set against a calm, abstract background that evokes scientific discovery and hope."
    }
  ]
}